Vitamin D receptor + Glucocorticoid receptor

Class

Vitamin D analog/corticosteroid fixed-dose combination (topical)

This combination pairs two nuclear hormone receptors targeted topically for chronic inflammatory skin conditions, principally psoriasis. The vitamin D receptor (VDR) is a transcription factor that, when bound by vitamin D or synthetic analogs, regulates genes controlling keratinocyte (skin cell) growth and maturation, correcting the excessive proliferation and abnormal differentiation seen in psoriatic plaques. The glucocorticoid receptor (GR) is bound by corticosteroids and, once activated, suppresses inflammatory gene expression, dampening the cytokine-driven immune activity that sustains psoriatic lesions. Used separately, vitamin D analogs act slowly and can irritate skin, while corticosteroids act quickly on inflammation but, with prolonged use, thin the skin (atrophy) and lose potency over time (tachyphylaxis). Combining agents that engage both receptors allows the anti-inflammatory, rapid-onset action of the corticosteroid to be paired with the differentiation-normalizing, disease-modifying action of the vitamin D analog, each mechanism offsetting some of the other's limitations. This dual-receptor approach broadly matters wherever a skin disease involves both hyperproliferation and inflammation, since single-pathway therapy addressing only one process tends to leave the other unresolved, limiting durability of response.